kras mutation and glutathion glynac

kras mutation and glutathion glynac Targeting KRAS: from metabolic regulation to cancer treatment | Molecular Cancer Oncometabolites in pancreatic cancer: Strategies

Name: kras mutation and glutathion glynac Targeting KRAS: from metabolic regulation to cancer treatment | Molecular Cancer Oncometabolites in pancreatic cancer: Strategies
Brand: lcog.de
SKU: 57831769785
Price: 22.47 USD
Availability: InStock
Rating: 4.5751 (13 reviews)

Oncometabolites in pancreatic cancer: Strategies and its implications PMC KRAS: feeding pancreatic cancer proliferation: Trends in Biochemical Sciences What should we know about the 'undruggable' target KRAS? MedChemExpress Treatment of KRAS Mutated Pancreatic Cancer: New Hope for the Patients? Glutathione Depletion and Stalwart Anticancer Activity of Metallotherapeutics Inducing Programmed Cell Death: Opening a New Window for Cancer Therapy ACS Omega

SKU: 57831769785 · From lcog.de

4.6

USD22.47 USD68.47

Pay in 4 interest-free payments of $5.62 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Jul 31 - Aug 5

Description

FRGS/1/2022/TK05/UPM/01/3

Hit Identification Hit Identification Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery

Fixed pigment concentrations (dark spots and other discolorations) will also be taken away

confirmed that TFAP2C regulated GPx1 expression by directly binding to the GPx1 promoter, which contains an AP-2 regulatory region, and the methylation of the CpG island in the GPx1 promoter region prevented the binding of TFAP2C by encompassing the AP-2 regulatory region [81]